More than 19,000 Novartis associates worldwide volunteer for local causes on Community Partnership Day

NovartisToday Novartis associates across 55 countries are engaging in local volunteer efforts to support their communities in celebration of the company's annual Community Partnership Day (CPD). This year marks the 18th Community Partnership Day commemorating the 1996 creation of Novartis as a global leader in healthcare. There is strong participation from all Novartis divisions in 2014. Alcon, the Novartis eyecare division, will celebrate Community Partnership Day in conjunction with World Sight Day on October 9, 2014, 5,000 associates are expected to participate.

Significant efforts will take place in major markets such as the United States, China, Brazil, Germany, Spain, the United Kingdom, India and Russia. Volunteers are also out in force in Bosnia and Herzegovina, Jordan, Lebanon, Nigeria and Iran.

Examples of volunteer service as part of this year's Community Partnership Day include:

  • More than 4,000 associates in Switzerland including 3,400 from the Basel region will participate in a range of voluntary projects in nursing homes and young adult support centers as well undertaking outdoor activities to improve local areas. In Nyon, associates have the option to take part in 12 different activities ranging from helping young adults to gain a foothold in the working world to environmental preservation.
  • In partnership with the UCL & UZ Hospital in Brussels, 250 associates in Belgium will provide support to patients and visitors by staging mini concerts in waiting rooms and organizing clowns to visit hospitalized children. They will give a special thank you to the 'invisible hands' - caregivers and staff.
  • Brazil is linking CPD back to the Novartis mission of caring and curing; 1,500 associates will provide care for Alzheimer patients, promote the leprosy elimination program in Brazil as well as immunization, a healthy lifestyle and animal vaccination.
  • Over 200 associates in Australia will undertake gardening and painting work for local organizations, packing hampers, donation drives and serving food in the community.
  • In Egypt, 150 associates will partner with a local organization helping people with disabilities find suitable employment. Associates will also fundraise for the Misr El Kheir Foundation, an Egyptian NGO working towards the development of Egyptian society in the areas of health, education, social solidarity, while fighting poverty and illiteracy.
  • In Russia, over 340 associates will be cleaning up the local area by collecting rubbish, maintaining gardens, planting flowers and painting outdoor areas.
  • At the Unterach site in Austria, over 100 associates will provide coaching on the job application process as well as offering science based lessons to local school children.
  • In New Jersey, USA 2,000 associates will partner with over 80 non-profit organizations such as the American Cancer Society, the Community FoodBank of New Jersey and The Servant Center, supporting homeless and disabled veterans to find transitional and permanent housing.
  • 250 associates in Mexico will volunteer in a range of activities from reforestation of the local area, visiting orphanages, health screening activities for inhabitants close to the Novartis site and support for the elderly.
  • In Thailand, 80 associates will accompany children from a Bangkok children's home on a day trip. Associates organized an auction and donation boxes to cover the cost of the children's lunch.
  • 260 associates in Spain are expected to donate blood, adapt a farm and farmland to provide housing and jobs to people suffering from intellectual disabilities and partake in sports for the disabled.
  • In Vietnam, over 150 associates will visit a local orphanage where they will organize sporting and craft activities for the children. They will also provide care packages to the poor.

About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2013, the Group achieved net sales of USD 57.9 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 135,000 full-time-equivalent associates and sell products in more than 150 countries around the world.

Most Popular Now

Most popular vitamin and mineral supplements provi…

The most commonly consumed vitamin and mineral supplements provide no consistent health benefit or harm, suggests a new study led by researchers at St. Michael's Hospital...

AstraZeneca heads to 2018 ASCO Annual Meeting with…

AstraZeneca and MedImmune, its global biologics research and development arm, head to the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US...

Tiny particles could help fight brain cancer

Glioblastoma multiforme, a type of brain tumor, is one of the most difficult-to-treat cancers. Only a handful of drugs are approved to treat glioblastoma, and the median ...

New approach to immunotherapy leads to complete re…

A novel approach to immunotherapy developed by researchers at the National Cancer Institute (NCI) has led to the complete regression of breast cancer in a patient who was...

Spiolto® Respimat® enables greater physical activi…

Boehringer Ingelheim announced data which add to the growing body of evidence that show Spiolto® (tiotropium/olodaterol) Respimat® enables greater physical activity in pa...

Amgen Foundation and Harvard team up to offer free…

The Amgen Foundation and Harvard University today announced plans to launch a free online science education platform uniquely designed to level the playing field for aspi...

The Pfizer Foundation announces $5 million in gran…

The Pfizer Foundation announced a new $5 million grant commitment to initiatives in low- and middle-income countries that provide family planning access and education for...

Study finds antioxidant-enriched vitamin reduces r…

Researchers at Children's Hospital Colorado (Children's Colorado) and the University of Colorado School of Medicine have found that taking a specially formulated antioxid...

New drugs could also be deployed against lung and …

A new anti-cancer drug may be effective against a wider range of cancers than previously thought. Using a mouse model and samples taken from cancer patients, a team from ...

What would help or hinder patient participation in…

As clinical trials gear up with the aim of attaining the first FDA-approved treatments for mitochondrial disease, a new study reports for the first time what patients and...

Pfizer to expand venture investing with $600 milli…

Pfizer Inc. (NYSE:PFE) today announced it plans to invest $600 million in biotechnology and other emerging growth companies through Pfizer Ventures, the company’s venture...

Update on Phase III clinical trials of lanabecesta…

AstraZeneca and Eli Lilly and Company (Lilly) are discontinuing the global Phase III clinical trials of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibi...